Résumé
CDK4/6 inhibitors in association with aromatase inhibitors have led to a paradigm shift in the management of metastatic positive hormone-receptors breast cancer. Liver toxicity is common with these agents, but no data are reported on the sequential use of these CDK4/6 inhibitors in case of confirmed efficacy and intolerable toxicity. In this article, we report the successful use of Palbociclib in a metastatic positive hormone-receptors breast cancer patient after initial response to Ribociclib, which was interrupted for grade 4 liver toxicity.
langue originale | Anglais |
---|---|
Pages (de - à) | 85-89 |
Nombre de pages | 5 |
journal | Anti-Cancer Drugs |
Volume | 31 |
Numéro de publication | 1 |
Les DOIs | |
état | Publié - 1 janv. 2020 |
Modification externe | Oui |